Basilea’s commercial portfolio is comprised of Cresemba (an antifungal) and Zevtera (an antibiotic). Cresemba is approved in 75 countries (marketed in 67 countries) and has Orphan Drug designation in the US, Europe and Australia. Zevtera is marketed in selected countries in Europe, Latin America, the Middle East, North Africa and Canada; the pending US approval remains a key strategic priority (the FDA has set a PDUFA goal date of 3 April 2024). In recent months, Basilea has introduced several new assets to re-stock its clinical pipeline. Most notably, fosmanogepix is a broad-spectrum antifungal therapy, for which, management intends to initiate Phase III trials from mid-2024. The company reported strong H123 results, with 47.3% y-o-y revenue growth to CHF84.9m, mainly led by higher royalty income and milestone payments related to Cresemba and Zevtera sales. Basilea has also recently shared FY23 revenue and operating profit guidance of CHF154–157m and CHF11–55m, respectively.